NCT05226442View on ClinicalTrials.gov

Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

July 7, 2024

Study Completion Date

July 7, 2024

Conditions
Extracorporeal Membrane Oxygenation ComplicationAnticoagulants and Bleeding Disorders
Interventions
DRUG

Argatroban

Argatroban is a synthetic, univalent DTI, that directly binds to the catalytic thrombin binding site exerting its effects

DRUG

Unfractionated heparin

Unfractionated heparin produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism.

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT05226442 - Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO | Biotech Hunter | Biotech Hunter